India's Pharmaceutical Armada

Description

India's Pharmaceutical Armada PR Newswire GURGAON, India and MADRID, Spain, October 9, 2012 GURGAON, India and MADRID, Spain, October 9, 2012 /PRNewswire/ -- Brand India Pharma in the Spotlight at CPhI Worldwide 2012 Having gained Focus Country status for CPhI exhibitions held globally, India the world's largest generic medicine manufacturer will be the cynosure of all eyes with its 'Brand India Pharma' campaign. The three-day CPhI Worldwide pharmaceuticals event will be held in Madrid from October 9-11. 'Brand India Pharma' CPhI Worldwide is the largest pharmaceutical trade exhibition organised each year by the UBM Group. UBM recognised India as the Focus Country across the CPhI exhibitions it has been organising globally, beginning with CPhI Japan in March 2012 followed by CPhI South East Asia held in Jakarta in May 2012 and finally CPhI Worldwide, which follows in October this year. CPhI Japan event, held during March 21-23, 2012 in Tokyo, was the launch-pad for the 'Brand India Pharma' campaign. The campaign is a significant initiative being led by Pharmexcil (Pharmaceutical Export Promotion Council of India) and IBEF (India Brand Equity Foundation) under the aegis of the Department of Commerce, Government of India, to highlight the value proposition that 'Brand India Pharma' presents today globally.

Informations

• Publié par: India-Brand-Equity-Foundation
• Nombre de lectures: 16
• Langue: English

Extrait

India's Pharmaceutical Armada

PR Newswire GURGAON, India and MADRID, Spain, October 9, 2012

GURGAON, India and MADRID, Spain,October 9, 2012/PRNewswire/ --

Brand India Pharma in the Spotlight at CPhI Worldwide 2012

Having gained Focus Country status for CPhI exhibitions held globally, India the world's largest generic medicine manufacturer will be the cynosure of all eyes with its'Brand India Pharma'campaign. The three-day CPhI Worldwide pharmaceuticals event will be held in Madrid fromOctober 9-11.

'Brand India Pharma' CPhI Worldwide is the largest pharmaceutical trade exhibition organised each year by the UBM Group. UB M recognised India as the Focus Country across the CP hI exhibitions it has been organising globally, beginning with CPhI Japan inMarch 2012Jakarta infollowed by CPhI South East Asia held in May 2012and finally CPhI Worldwide, which follows in October this year.

CPhI Japan event, held duringMarch 21-23, 2012in Tokyo, was the launch-pad for the 'BrandIndiaPharma'campaign. The campaign is a significant initiative being led by Pharmexcil (Pharmaceutical Export Promotion Council of India) and IBEF (India Brand Equity Foundation) under the aegis of the Department of Commerce, Government of India, to highlight the value proposition that 'BrandIndiaPharma'presents today globally.

These events present an opportunity for various business groups for enhancing business growth in the pharmaceutical space by networking and thought sharing with leading pharmaceutical companies from across the globe brought together by CPhI.

Participation from over 200 Indian pharmaceutical companies is expected at theMadrid eventspread across all segments of the industry. The Indian presence at Madrid will be led by Mr. S R Rao, Commerce Secretary, Ministry of Commerce and Industry, Government of India, who will be accompanied by senior officials of the Department of Commerce and a large Indian business contingent.

With the global pharmaceutical market growing at 5% , India is making massive strides in the pharmaceutical sector by clocking a growth rate of 10%, double the global growth rate in the sector. According to a PricewaterhouseCoopers report, India's current pharmaceutical market size is aroundUS$ 11 billion, global market size beingUS$ 880 billion, and is expected to reachUS$ 74 billionby 2020.

India has been exporting to regulated markets, which majorly comprises the US and the European Union, apart from Oceania and Japan. In the unregulated sector, Latin America, Africa and parts of Asia comprise of the market. While there is a huge potential in the regulated markets, the events of the past 3-4 years have demonstrated the necessity for diversification. India aims to double its exports to reachUS$ 500 billionby 2014, the share of pharmaceutical exports is expected to be a robust 5% of the total target atUS$ 25 billion.

At a sustained growth rate of 10%,India has arrived at the global pharmaceutical arena as a hub for all pharmaceutical manufacturing and research needs. Today, there are 475 USFDA (U.S. Food and Drug Administration) approved manufacturing facilities in India.

India's growing per-capita income, stable economy, and government's active support to the pharmaceutical sector, make India a very lucrative investment destination for pharmaceuticals businesses seeking newer growth opportunities.

Biocon, Dr. Reddy's Laboratories, and Aurobindo Pharma are some leading Indian companies in the pharmaceutical domain registering annual revenue of close toUS$ 1 billioneach.

Pfizer (USA), GlaxoSmithKline (UK), Novartis (Switzerland), Bayer (Germany), Sanofi-Aventis (France), Johnson & Johnson (USA) are some of the leading international pharmaceutical companies having successful business presence in India.

India's rising disposable income, improving medical infrastructure, greater health insurance penetration, shift in disease profile, and growth in population will play a key role in ensuring India's dominance in the global

pharmaceutical space in the days ahead.

Additionally, the Government of India has undertaken various initiatives to bolster growth in the pharmaceutical sector. Specifically, steps like tax incentives and grants for bio-technology start-ups, permitting 100% FDI (Foreign Direct Investment) in pharmaceutical sector, and the unveiling of a plan to set up aRs 2,000 croreventure capital fund to promote drug discovery and strengthen infrastructure have had far reaching effects in making'Brand India Pharma'synonymous with quality, affordable and sustainable healthcare.

For further information please visithttp://www.brandindiapharma.in/.

About India Brand Equity Foundation (IBEF):

India Brand Equity Foundationis a Trust established by the Ministry of Commerce with the Confederation of Indian Industry (CII) as its associate. IBEF's primary objective is to promote and create international awareness of theMade in Indialabel in markets overseas and to facilitate the dissemination of knowledge of Indian products and services. IBEF is engaged in building Brand India. Towards this objective, IBEF works closely with stakeholders across government and industry.

Primary Media Contact: Aditi Thakur,[e-mail], 91-9818143259

Secondary Media Contact: Pawan Chabra,[e-mail], 91-124-4499600